Application

Immunohistochemistry (Paraffin) Analysis: A 1:10 dilution from a representative lot detected YAP1 in human placenta, human pancreatic cancer, and mouse colon tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected YAP1 in HUVEC, HeLa, A431, and NIH 3T3 cells.

Anti-YAP1, clone 4F22, ZooMAb, Cat. No. ZRB1001, is a recombinant Rabbit Monoclonal Antibody that specifically targets Transcriptional coactivator YAP1 and has been tested for use in Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

His-tagged recombinant fragment corresponding to 148 amino acids from the C-terminal half of human Transcriptional coactivator YAP1.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

30 µg/mL after reconstitution at 25 µL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 4F22 is a ZooMab rabbit recombinant monoclonal antibody that specifically detects human and murine Transcriptional coactivator YAP1.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Transcriptional coactivator YAP1 (UniProt: P46937; also known as Yes-associated protein 1, Protein yorkie homolog, Yes-associated protein YAP65 homolog) is encoded by the YAP1 (also known as YAP65) gene (Gene ID: 10413) in human. YAP1 is a transcriptional regulator that can act both as a coactivator and a corepressor and is the critical downstream regulatory target in the Hippo signaling pathway. It also plays a key role in tissue tension and 3D tissue shape by regulating cortical actomyosin network formation. YAP1 contains two WW domains (aa 171-204 and 230-263) and a transactivation domain (aa 291-504). It also has two coiled coil regions (aa 86-100 and 298-359) and the first coiled-coil region is reported to mediate most of the interaction with TEAD transcription factors. The presence of TEAD transcription factors is required for YAP1 to stimulate gene expression, cell growth, anchorage-independent growth, and epithelial mesenchymal transition (EMT) induction. YAP1 phosphorylation status and cell density can regulate its subcellular localization. Its phosphorylation by LATS1 and LATS2 leads to its cytoplasmic translocation and inactivation. YAP1 can also be phosphorylated by ABL1, which leads to its stabilization, increased interaction with TP73, and recruitment onto proapoptotic genes in response to DNA damage. Nine isoforms of YAP1 have been described that are produced by alternative splicing. Mutations in YAP1 gene have been linked to ocular coloboma that is characterized by uveal colobomata, microphthalmia, cataract and cleft lip/palate. Higher expression of YAP1 has been reported in some liver and prostate cancers. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.